Side-by-side research comparison of TB-500 and Thymosin Alpha-1 across our PubMed, ClinicalTrials.gov, and EuropePMC corpus. 1 head-to-head study plus 12 on TB-500 and 88 on Thymosin Alpha-1.
| TB-500 | Thymosin Alpha-1 | |
|---|---|---|
| Drug class | healing peptide, thymosin | thymosin, immune modulator |
| Studies in corpus | 12 | 88 |
| Highest evidence tier | review | rct |
| Evidence tier mix | review · 2 in vitro · 3 other · 4 | other · 33 rct · 26 in vitro · 5 case series · 4 cohort · 2 preclinical animal · 6 review · 4 case report · 3 |
| Studies with explicit sample size | 0 | 10 |
| Head-to-head studies in corpus | 1 | |
Beyond the literature: here's what third-party Certificate-of-Analysis records (Janoshik, BCC, Auxlabs) say about real TB-500 and Thymosin Alpha-1 batches we've tested. Aggregate, public data — cross-reference against the studies below.
We tested 2467 TB-500 batches across 828 manufacturers, 98.97% avg purity.
We tested 5 Thymosin Alpha-1 batches across 2 manufacturers, 99.8% avg purity.
We hold deeper lab coverage on TB-500 (2467 batches tested). Thymosin Alpha-1 edges ahead on average measured purity (98.97% vs 99.8%) — a narrow gap; weigh it against failed-batch and underdose counts above.
Studies in our corpus that mention both TB-500 and Thymosin Alpha-1 — the gold-standard direct comparison evidence.
Looking for vendor-level purity, endotoxin, and HPLC data on TB-500 or Thymosin Alpha-1? TitrateLab tracks Certificate-of-Analysis records from the major peptide labs (Janoshik, BCC, Auxlabs) alongside the research above. Cross-reference vendor batches against the studies on this page.